PacBio to Report Third Quarter Earnings on November 7 and Host Inaugural Investor Day on November 15

Withdraws Guidance with New Product Announcement

MENLO PARK, Calif., Oct. 25, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2022 financial results on Monday, Nov. 7, 2022, at 5:00 p.m. Eastern Time.

PacBio will also host its Inaugural Investor Day on Tuesday, Nov. 15, 2022, at 8:00 a.m. Eastern Time. The event will feature presentations by members of PacBio's executive team and include Q&A sessions.

Both events will be webcast live and may be accessed at PacBio's website at:  https://investor.pacificbiosciences.com/.

Date: Monday, Nov. 7, 2022 at 5:00 p.m. ET (2:00 p.m. PT)
Listen live via internet or replay: https://investor.pacificbiosciences.com/
Toll-free: 866-652-5200
International: 412-317-6060

If using the dial-in option, please dial into the call five to ten minutes prior to start time using the appropriate number above and ask to join the "PacBio Q3 Earnings Call."

Date: Tuesday, Nov. 15, 2022 at 8:00 a.m. ET (5:00 a.m. PT)
Location: The St. Regis Hotel, Two E 55th Street, New York, NY 10022
Listen via internet or replay:  https://investor.pacificbiosciences.com/

In light of forthcoming product announcements, we are withdrawing all prior financial guidance. We plan to provide additional information during our third quarter earnings call on Nov. 7, 2022.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our existing HiFi long read sequencing and our emerging SBB™ short read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements relating to forthcoming product announcements and plans to provide additional information during our third quarter earnings call. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results.  Factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

Contacts
Investors:
Todd Friedman
650.521.8450
[email protected] 

Media:
Lizelda Lopez
[email protected]

SOURCE Pacific Biosciences of California, Inc.